Wen-Yang Tsai1, Han Ha Youn1, Carlos Brites2, Jih-Jin Tsai3,4,5,6, Jasmine Tyson1, Celia Pedroso2, Jan Felix Drexler7,8, Mars Stone9, Graham Simmons9,10, Michael P Busch9,10, Marion Lanteri9,10, Susan L Stramer11, Angel Balmaseda12, Eva Harris13, Wei-Kung Wang1. 1. Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu. 2. Laboratory of Infection Research, School of Medicine, Federal University of Bahia, Salvador, Brazil. 3. Divison of Infectious Diseases. 4. Department of Internal Medicine and Tropical Medicine Center, Kaohsiung Medical University Hospital. 5. Department of Medicine, College of Medicine. 6. Center for Dengue Fever Control and Research, Kaohsiung Medical University, Taiwan. 7. University of Bonn Medical Centre, Institute of Virology. 8. German Centre for Infection Research, Bonn-Cologne, Germany. 9. Blood Systems Research Institute. 10. University of California, San Francisco. 11. American Red Cross Scientific Support Office, Gaithersburg, Maryland. 12. National Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua. 13. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley.
Abstract
BACKGROUND: The explosive spread of Zika virus (ZIKV) and associated microcephaly present an urgent need for sensitive and specific serodiagnostic tests, particularly for pregnant women in dengue virus (DENV)-endemic regions. Recent reports of enhanced ZIKV replication by dengue-immune sera have raised concerns about the role of previous DENV infection on the risk and severity of microcephaly and other ZIKV complications. METHODS: Enzyme-linked immunosorbent assays (ELISAs) based on ZIKV and DENV nonstructural protein 1 (NS1) were established to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-transcription polymerase chain reaction-confirmed cases including 20 primary ZIKV, 25 ZIKV with previous DENV, 58 secondary DENV, and 16 primary DENV1 infections. RESULTS: ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs combined can detect ZIKV infection with a sensitivity of 95% and specificity of 66.7%. The ZIKV-NS1 IgG cross-reactivity by samples from secondary DENV infection cases ranged from 66.7% to 28.1% (within 1 month to 1-2 years post-illness, respectively). Addition of DENV1-NS1 IgG ELISA can distinguish primary ZIKV infection; the ratio of absorbance of ZIKV-NS1 to DENV1-NS1 IgG ELISA can distinguish ZIKV with previous DENV and secondary DENV infections with a sensitivity of 87.5% and specificity of 81.3%. These findings were supported by analysis of sequential samples. CONCLUSIONS: An algorithm for ZIKV serodiagnosis based on 3 simple ELISAs is proposed to distinguish primary ZIKV, ZIKV with previous DENV, and secondary DENV infections; this could be applied to serodiagnosis for ZIKV, serosurveillance, and monitoring ZIKV infection during pregnancy to understand the epidemiology, pathogenesis, and complications of ZIKV in dengue-endemic regions.
BACKGROUND: The explosive spread of Zika virus (ZIKV) and associated microcephaly present an urgent need for sensitive and specific serodiagnostic tests, particularly for pregnant women in dengue virus (DENV)-endemic regions. Recent reports of enhanced ZIKV replication by dengue-immune sera have raised concerns about the role of previous DENV infection on the risk and severity of microcephaly and other ZIKV complications. METHODS: Enzyme-linked immunosorbent assays (ELISAs) based on ZIKV and DENV nonstructural protein 1 (NS1) were established to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-transcription polymerase chain reaction-confirmed cases including 20 primary ZIKV, 25 ZIKV with previous DENV, 58 secondary DENV, and 16 primary DENV1 infections. RESULTS: ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs combined can detect ZIKV infection with a sensitivity of 95% and specificity of 66.7%. The ZIKV-NS1 IgG cross-reactivity by samples from secondary DENV infection cases ranged from 66.7% to 28.1% (within 1 month to 1-2 years post-illness, respectively). Addition of DENV1-NS1 IgG ELISA can distinguish primary ZIKV infection; the ratio of absorbance of ZIKV-NS1 to DENV1-NS1 IgG ELISA can distinguish ZIKV with previous DENV and secondary DENV infections with a sensitivity of 87.5% and specificity of 81.3%. These findings were supported by analysis of sequential samples. CONCLUSIONS: An algorithm for ZIKV serodiagnosis based on 3 simple ELISAs is proposed to distinguish primary ZIKV, ZIKV with previous DENV, and secondary DENV infections; this could be applied to serodiagnosis for ZIKV, serosurveillance, and monitoring ZIKV infection during pregnancy to understand the epidemiology, pathogenesis, and complications of ZIKV in dengue-endemic regions.
Authors: Karin Stettler; Martina Beltramello; Diego A Espinosa; Victoria Graham; Antonino Cassotta; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Stefano Jaconi; Federico Mele; Mathilde Foglierini; Mattia Pedotti; Luca Simonelli; Stuart Dowall; Barry Atkinson; Elena Percivalle; Cameron P Simmons; Luca Varani; Johannes Blum; Fausto Baldanti; Elisabetta Cameroni; Roger Hewson; Eva Harris; Antonio Lanzavecchia; Federica Sallusto; Davide Corti Journal: Science Date: 2016-07-14 Impact factor: 47.728
Authors: Vanessa van der Linden; André Pessoa; William Dobyns; A James Barkovich; Hélio van der Linden Júnior; Epitacio Leite Rolim Filho; Erlane Marques Ribeiro; Mariana de Carvalho Leal; Pablo Picasso de Araújo Coimbra; Maria de Fátima Viana Vasco Aragão; Islane Verçosa; Camila Ventura; Regina Coeli Ramos; Danielle Di Cavalcanti Sousa Cruz; Marli Tenório Cordeiro; Vivian Maria Ribeiro Mota; Mary Dott; Christina Hillard; Cynthia A Moore Journal: MMWR Morb Mortal Wkly Rep Date: 2016-12-02 Impact factor: 17.586
Authors: Margaret A Honein; April L Dawson; Emily E Petersen; Abbey M Jones; Ellen H Lee; Mahsa M Yazdy; Nina Ahmad; Jennifer Macdonald; Nicole Evert; Andrea Bingham; Sascha R Ellington; Carrie K Shapiro-Mendoza; Titilope Oduyebo; Anne D Fine; Catherine M Brown; Jamie N Sommer; Jyoti Gupta; Philip Cavicchia; Sally Slavinski; Jennifer L White; S Michele Owen; Lyle R Petersen; Coleen Boyle; Dana Meaney-Delman; Denise J Jamieson Journal: JAMA Date: 2017-01-03 Impact factor: 56.272
Authors: Ingrid B Rabe; J Erin Staples; Julie Villanueva; Kimberly B Hummel; Jeffrey A Johnson; Laura Rose; Susan Hills; Annemarie Wasley; Marc Fischer; Ann M Powers Journal: MMWR Morb Mortal Wkly Rep Date: 2016-06-03 Impact factor: 17.586
Authors: Johanna Jarmer; Jürgen Zlatkovic; Georgios Tsouchnikas; Oksana Vratskikh; Judith Strauß; Judith H Aberle; Vaclav Chmelik; Michael Kundi; Karin Stiasny; Franz X Heinz Journal: J Virol Date: 2014-09-24 Impact factor: 5.103
Authors: William J Lew; Wen-Yang Tsai; Venkataraman Balaraman; Kore Kai Liow; Jasmine Tyson; Wei-Kung Wang Journal: Hawaii J Med Public Health Date: 2019-04
Authors: Jasmine Tyson; Wen-Yang Tsai; Jih-Jin Tsai; Carlos Brites; Ludvig Mässgård; Han Ha Youn; Celia Pedroso; Jan Felix Drexler; Susan L Stramer; Angel Balmaseda; Eva Harris; Wei-Kung Wang Journal: J Clin Microbiol Date: 2019-01-30 Impact factor: 5.948
Authors: Szu-Chia Hsieh; Wen-Yang Tsai; Jih-Jin Tsai; Mars Stone; Graham Simmons; Michael P Busch; Marion Lanteri; Susan L Stramer; Angel Balmaseda; Eva Harris; Wei-Kung Wang Journal: J Virol Date: 2021-09-09 Impact factor: 5.103